AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01847924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 weeks intervention with orally placebo. 2 capsules 3 times a day
Study NCT03730740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25mg
Description: Lenalidomide 25mg, day 1 - day 21 (1cycle=28days) for 2yeas
Study NCT03110016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: The participants use SPSRS to watch the motion picture for at least 10 min a day for 5 weeks.
Study NCT01962649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICG
Study NCT01962649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical molecular imaging
Study NCT03710096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: macGrath
Description: in the mac grath group we use the videolaryngoscope macGrath as first-line for the insertion of double lumen tube
Study NCT03710096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh's
Description: in the macintosh group we use the laryngoscope with Macintosh's blade as first-line for the insertion of double lumen tube
Study NCT04010734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography
Description: The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH).
Study NCT04204343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.7 ml/kg
Description: Bupivacaine 0.25% 0.7 ml/kg
Study NCT04204343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5 ml/kg
Description: Bupivacaine 0.25% 0.5 ml/kg
Study NCT04185064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game Ready ATX shoulder wrap; Game Ready GRPro 2.1
Description: the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.
Study NCT04185064 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Game Ready ATX shoulder wrap; Game Ready GRPro 2.1
Description: the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.
Study NCT04185064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will undergo post-surgical cryotherapy using the treating surgeons preferred method of cryotherapy, which can include rest, ice, and compression using standard ice packs or bag of ice, a cryocuff, or other such device.
Study NCT01193699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-P-INF alpha-2b (P1101)
Description: µg (starting with 50 µg), subcutaneously, 2-weekly administration
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: * Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).~* The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).~* creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
Description: * Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.
Study NCT02793544 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation (TBI) 200cGy on Day -1
Description: * 200 cGy TBI is administered in a single fraction on Day -1.~* Radiation sources, dose rates, and shielding follow institutional practice.
Study NCT02793544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of non-T-cell depleted bone marrow on Day 0
Description: * On Day 0, the harvested bone marrow is infused.~* Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.~* The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: * Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM\*min (Perkins et al., 2012))~* Busulfan dosing is based on adjusted IBW (Appendix K)
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 50mg/kg/day IV on Days -2,-1
Description: * Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 50mg/kg/day IV on Days -5,-4
Description: * Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight.
Study NCT02793544 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1
Description: * 200cGy TBI is administered in twice daily on Days -3, -2, and -1.~* Radiation sources, dose rates, and shielding follow institutional practice.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4
Description: * Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~* Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~* Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: * Sirolimus dosing is based on adjusted IBW (Appendix K).~* Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.~For subjects ≥ 18 years old:~* A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.~For subjects \< 18 years old:~* A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-HCT Mesna on Days -6 and -5
Description: Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-HCT Mesna on Days -2 and -1
Description: Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-HCT Mesna on Days -5 and -4
Description: Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight.
Study NCT02793544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-HCT Mesna
Description: Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight.
Study NCT03583697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol
Study NCT03583697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
Study NCT04184713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.
Study NCT04184713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.
Study NCT00608660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: staging acupuncture
Study NCT00608660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture and moxibustion
Description: staging acupuncture and moxibustion
Study NCT00608660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: staging electroacupuncture
Study NCT00608660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture along yangming tendons
Description: staging acupuncture along Yangming musculature
Study NCT00608660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: non-staging acupuncture
Study NCT04721171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Bridge device
Description: he Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
Study NCT04721171 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: The Bridge device
Description: he Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
Study NCT01457144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiBVD
Description: Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2
Study NCT01228474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Select the Number of embryos to transfer
Description: Select the Number of embryos to transfer
Study NCT01228474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Select the Number of embryos to transfer
Description: Select the Number of embryos to transfer
Study NCT01753141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for smoking cessation
Study NCT01753141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.
Description: Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
Study NCT02084212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Microperimetry
Study NCT02423109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: contact lens
Study NCT02214199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulative Therapy Techniques
Study NCT02214199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercises
Study NCT02423109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A
Description: contact lens
Study NCT03161678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
Study NCT03161678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
Study NCT03161678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
Study NCT03161678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
Study NCT03136549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermo-softening
Description: The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
Study NCT03136549 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room temperature
Description: nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
Study NCT03767062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax
Description: An antiepileptic agent used for migraine prophylaxis.
Study NCT03767062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater Occipital Nerve Block + Supratrochlear Nerve Block
Description: An injection to paralyze the occipital and supratrochlear nerves.
Study NCT02423109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: contact lens
Study NCT02423109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enfilcon A
Description: contact lens
Study NCT04561336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: avelumab in combination with cetuximab
Study NCT04561336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: avelumab in combination with cetuximab
Study NCT01706263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Cleanser
Description: Available over the counter.
Study NCT01706263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Treatment
Description: Available over the counter.
Study NCT01706263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
Description: Available over the counter.
Study NCT01477424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Description: The maximum dose of PA21 will be 15.0 g/day.
Study NCT01477424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: The maximum dosage of Warfarin will be 10 mg/day
Study NCT04643392 — intervention group
Intervention type: PROCEDURE
Intervention: Complex decongestive physiotherapy
Description: Each patient received a treatment protocol of Complex decongestive physiotherapy for 5 days a week until they were discharged from the clinic. All patients fully completed all components of the treatment routine daily. The treatment was performed by a physiotherapist who was certified with Manual Lymph Drainage Combined Decongestive Physiotherapy. After the daily treatment protocol was completed, patients wore standard or individually sized compression grade II or III medical compression stockings for the rest of the day.
Study NCT00931996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic
Description: Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
Study NCT01413763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod cream 3.75%
Description: 3.75% cream, applied daily for 2 weeks
Study NCT01413763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: placebo cream applied daily for 2 weeks
Study NCT02330744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach-positive AAT
Description: One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
Study NCT02330744 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control AAT
Description: One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).